🔎 Trials Near Me

Home › Wilms Tumor › California

Pag-aaral pangklinika para sa Wilms Tumor sa California

5 pag-aaral para sa Wilms Tumor ang naghahanap ng mga kalahok sa mga site sa California.

Mga Lungsod sa California

Opisyal na teksto ng pag-aaral (English)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • Children's Hospital Los Angeles, Los Angeles
  • Lucile Packard Children's Hospital Stanford University, Palo Alto
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT04616560

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • Kaiser Permanente Downey Medical Center, Downey
  • Loma Linda University Medical Center, Loma Linda
  • Miller Children's and Women's Hospital Long Beach, Long Beach
  • at 11 pa
Nagre-recruitPhase 2
Hanggang edad 30 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04322318

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Hospital Los Angeles, Los Angeles
  • Children's Hospital of Orange County, Orange
  • UCSF Medical Center-Mission Bay, San Francisco
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

  • Lucille Packard Children's Hospital Stanford, Palo Alto
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update May 19, 2026 · NCT04901702

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

  • Children's Hospital of Los Angeles (Data Collection Only), Los Angeles
  • Stanford Medicine Children's Health (Data Collection Only), Palo Alto
Nagre-recruitPhase 2
12 Months · Lahat ng kasarian · Na-update May 6, 2026 · NCT05985161

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.